Skip to main content
SpringerLink
Log in

High Dose Rate Prostate Brachytherapy

  • Chapter
  • First Online:
Radiation Therapy for Genitourinary Malignancies

Part of the book series: Practical Guides in Radiation Oncology ((PGRO))

  • 633 Accesses

Abstract

High Dose Rate (HDR) brachytherapy is a safe and effective method of treating men with prostate cancer. It is used in the definitive setting as monotherapy or in combination with hormonal therapy and/or external beam radiation therapy. It is also used in the salvage setting for local recurrence after primary radiotherapy. The best HDR brachytherapy treatments are performed by providers that understand ideal patient selection, appropriate operative practices, and optimal treatment planning. This chapter will discuss the history, rationale, pertinent anatomy, patient selection, operative procedure, treatment planning, clinical outcomes, and follow-up practices that will help ensure the reader is best positioned to leverage the benefits HDR brachytherapy can provide in treating prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Erickson BA, Bittner NH, Chadha M, Mourtada F, Demanes DJ (2017) The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy. Brachytherapy 16(1):75–84. https://doi.org/10.1016/j.brachy.2016.05.006

    Article  PubMed  Google Scholar 

  2. National Comprehensive Cancer Network (2020) NCCN clinical practice guidelines in oncology (NCCN Guidelines®) prostate cancer 2020 Version 1.2020. National Comprehensive Cancer Network, Fort Washington, PA

    Google Scholar 

  3. Chen RC, Basak R, Meyer AM et al (2017) Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA 317:1141. https://doi.org/10.1001/jama.2017.1652

    Article  PubMed  PubMed Central  Google Scholar 

  4. Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high-risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109(Suppl 1):22–29. https://doi.org/10.1111/j.1464-410X.2011.10827.

    Article  PubMed  Google Scholar 

  5. Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. https://doi.org/10.1056/NEJMoa1606220

    Article  PubMed  Google Scholar 

  6. Donovan JL, Hamdy FC, Lane JA et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375(15):1425–1437. https://doi.org/10.1056/NEJMoa1606221

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sanda MG, Dunn RL, Michalski J et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250–1261. https://doi.org/10.1056/NEJMoa074311

    Article  CAS  PubMed  Google Scholar 

  8. Stromberg J, Martinez A, Gonzalez J et al (1995) Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 33(1):161–171. https://doi.org/10.1016/0360-3016(95)00035-w

    Article  CAS  PubMed  Google Scholar 

  9. Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L (1998) High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 41(3):525–533. https://doi.org/10.1016/s0360-3016(98)00097-2

    Article  CAS  PubMed  Google Scholar 

  10. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G (2005) High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 61(5):1306–1316. https://doi.org/10.1016/j.ijrobp.2004.08.014

    Article  PubMed  Google Scholar 

  11. Yoshioka Y, Nose T, Yoshida K et al (2000) High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 48(3):675–681. https://doi.org/10.1016/s0360-3016(00)00687-8

    Article  CAS  PubMed  Google Scholar 

  12. Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G (2001) Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 49(1):61–69. https://doi.org/10.1016/s0360-3016(00)01463-2

    Article  CAS  PubMed  Google Scholar 

  13. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS (2010) High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 33(5):481–488. https://doi.org/10.1097/COC.0b013e3181b9cd2f

    Article  PubMed  Google Scholar 

  14. Martin T, Baltas D, Kurek R et al (2004) 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 180(4):225–232. https://doi.org/10.1007/s00066-004-1215-4

    Article  PubMed  Google Scholar 

  15. Solanki AA, Mysz ML, Patel R et al (2018) Transitioning from a low-dose-rate to a high-dose-rate prostate brachytherapy program: comparing initial dosimetry and improving workflow efficiency through targeted interventions. Adv Radiat Oncol 4(1):103–111. https://doi.org/10.1016/j.adro.2018.10.004

    Article  PubMed  PubMed Central  Google Scholar 

  16. White EC, Kamrava MR, Demarco J et al (2013) High-dose-rate prostate brachytherapy consistently results in high quality dosimetry. Int J Radiat Oncol Biol Phys 85(2):543–548. https://doi.org/10.1016/j.ijrobp.2012.03.035

    Article  PubMed  Google Scholar 

  17. Major T, Polgár C, Jorgo K, Stelczer G, Ágoston P (2017) Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: initial findings of a randomized clinical trial. Brachytherapy 16(3):608–615. https://doi.org/10.1016/j.brachy.2017.02.003

    Article  CAS  PubMed  Google Scholar 

  18. Skowronek J (2013) Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options. J Contemp Brachytherapy 5(1):33–41. https://doi.org/10.5114/jcb.2013.34342

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hentz C, Mark K, Martin B et al (2017) HDR prostate brachytherapy is associated with lower urinary toxicity and more rapid resolution over the first year compared to LDR brachytherapy. Int J Radiat Oncol 99(2):E238. https://doi.org/10.1016/j.ijrobp.2017.06.1173

    Article  Google Scholar 

  20. Grills IS, Martinez AA, Hollander M et al (2004) High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171(3):1098–1104. https://doi.org/10.1097/01.ju.0000113299.34404.22

    Article  PubMed  Google Scholar 

  21. Hathout L, Mahmoud O, Wang Y et al (2019) A phase 2 randomized pilot study comparing high-dose-rate brachytherapy and low-dose-rate brachytherapy as monotherapy in localized prostate cancer. Adv Radiat Oncol 4(4):631–640. https://doi.org/10.1016/j.adro.2019.04.003

    Article  PubMed  PubMed Central  Google Scholar 

  22. Carlone M, Rink A, Beiki-Ardakani A et al (2016) MR-guided high-dose-rate (HDR) brachytherapy: simultaneous integrated focal boost to intra-prostatic GTV(s). Brachytherapy 15(2016):S51–S52. https://doi.org/10.1016/j.brachy.2016.04.065

    Article  Google Scholar 

  23. Yamada Y, Rogers L, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11(1):20–32. https://doi.org/10.1016/j.brachy.2011.09.008

    Article  PubMed  Google Scholar 

  24. Davis BJ, Horwitz EM, Lee WR et al (2012) American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11(1):6–19. https://doi.org/10.1016/j.brachy.2011.07.005

    Article  PubMed  Google Scholar 

  25. Blasko JC, Ragde H, Grimm PD (1991) Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl 137:113–118

    CAS  PubMed  Google Scholar 

  26. Talcott JA, Clark JA, Stark PC, Mitchell SP (2001) Long-term treatment-related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 166:494–499

    Article  CAS  PubMed  Google Scholar 

  27. Luo HL, Fang FM, Chuang YC, Chiang PH (2009) Previous transurethral resection of the prostate is not a contraindication to high-dose rate brachytherapy for prostate cancer. BJU Int 104(11):1620–1623. https://doi.org/10.1111/j.1464-410X.2009.08664.

    Article  PubMed  Google Scholar 

  28. Peddada AV, Jennings SB, Faricy PO, Walsh RA, White GA, Monroe AT (2007) Low morbidity following high dose rate brachytherapy in the setting of prior transurethral prostate resection. J Urol 178(5):1963–1967. https://doi.org/10.1016/j.juro.2007.07.028

    Article  PubMed  Google Scholar 

  29. Pham YD, Kittel JA, Reddy CA et al (2016) Outcomes for prostate glands >60 cc treated with low-dose-rate brachytherapy. Brachytherapy 15(2):163–168. https://doi.org/10.1016/j.brachy.2015.12.002

    Article  PubMed  Google Scholar 

  30. Gibbons EP, Smith RP, Beriwal S et al (2009) Overcoming pubic arch interference with free-hand needle placement in men undergoing prostate brachytherapy. Brachytherapy 8:74–78

    Article  PubMed  Google Scholar 

  31. Le H, Rojas A, Alonzi R et al (2013) The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer. Int J Radiat Oncol Biol Phys 87(2):270–274. https://doi.org/10.1016/j.ijrobp.2013.05.022

    Article  PubMed  Google Scholar 

  32. Monroe AT, Faricy PO, Jennings SB et al (2008) High-dose-rate brachytherapy for large prostate volumes (> or =50cc)-uncompromised dosimetric coverage and acceptable toxicity. Brachytherapy 7:7–1

    Article  PubMed  Google Scholar 

  33. Press RH, Morgan TM, Cutrell PK et al (2019) Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands. Brachytherapy 18(1):13–21. https://doi.org/10.1016/j.brachy.2018.08.009

    Article  PubMed  Google Scholar 

  34. Harris AA, Martin B, Stang K et al (2018) Impact of prostate gland size ≥60 cc on physician and patient-reported toxicity after high dose rate prostate brachytherapy. Int J Radiat Oncol 102(3):e116. https://doi.org/10.1016/j.ijrobp.2018.07.315

    Article  Google Scholar 

  35. Crook J, McLean M, Catton C et al (2002) Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52:453–460

    Article  PubMed  Google Scholar 

  36. Terk M, Stock R, Stone N (1998) Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 160:1379–1382

    Article  CAS  PubMed  Google Scholar 

  37. Morgan TM, Rossi PJ, Cutrell PK et al (2019) High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores. Brachytherapy 18(6):793–799. https://doi.org/10.1016/j.brachy.2019.06.001

    Article  PubMed  Google Scholar 

  38. Yamada Y, Bhatia S, Zaider M et al (2006) Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 5:157–164

    Article  PubMed  Google Scholar 

  39. Harris AA, Baldea K, Farooq A, Flanigan R, Harkenrider MM, Solanki AA (2019) Exploring the impact of high baseline IPSS on urinary, bowel, and sexual function in the first year after prostate high dose rate brachytherapy. Brachytherapy 18(3):S75. https://doi.org/10.1016/j.brachy.2019.04.157

    Article  Google Scholar 

  40. Pedley ID (2002) Transperineal interstitial permanent prostate brachytherapy for carcinoma of the prostate. Surg Oncol 11(1–2):25–34. https://doi.org/10.1016/s0960-7404(02)00010-5

    Article  PubMed  Google Scholar 

  41. Wallner K, Smathers S, Sutlief S, Corman J, Ellis W (2000) Prostate brachytherapy in patients with median lobe hyperplasia. Int J Cancer 90(3):152–156

    Article  CAS  PubMed  Google Scholar 

  42. Amin PP, Naslund M, Vyas S (2011) Permanent brachytherapy of prostates with median lobe hyperplasia. Brachytherapy 10(2011):S89. https://doi.org/10.1016/j.brachy.2011.02.177

    Article  Google Scholar 

  43. Song DY, Lawrie WT, Abrams RA et al (2001) Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys 51:455–459

    Article  CAS  PubMed  Google Scholar 

  44. Pai HH, Keyes M, Morris WJ, Christie J (2013) Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease. Brachytherapy 12(2):126–133. https://doi.org/10.1016/j.brachy.2012.04.008

    Article  PubMed  Google Scholar 

  45. Mohammed W, Hoskin P, Henry A, Gomez-Iturriaga A, Robinson A, Nikapota A (2018) Short-term toxicity of high dose rate brachytherapy in prostate cancer patients with inflammatory bowel disease. Clin Oncol 30(9):534–538. https://doi.org/10.1016/j.clon.2018.06.007

    Article  CAS  Google Scholar 

  46. Morton GC (2015) Prostate high-dose-rate brachytherapy: transrectal ultrasound based planning, a technical note. Pract Radiat Oncol 5(4):238–240. https://doi.org/10.1016/j.prro.2014.12.009

    Article  PubMed  Google Scholar 

  47. Sandler HM, Bree RL, McLaughlin PW, Grossman HB, Lichter AS (1993) Localization of the prostatic apex for radiation therapy using implanted markers. Int J Radiat Oncol Biol Phys 27(4):915–919. https://doi.org/10.1016/0360-3016(93)90468-b

    Article  CAS  PubMed  Google Scholar 

  48. Mitterberger M, Horninger W, Aigner F et al (2010) Ultrasound of the prostate. Cancer Imag 10(1):40–48. https://doi.org/10.1102/1470-7330.2010.0004

    Article  Google Scholar 

  49. Saigal K, All S, Potrebko P et al (2019) Incorporating routine magnetic resonance imaging-based planning for the delivery of high-dose-rate brachytherapy for prostate cancer: an evaluation of clinical feasibility and dosimetric outcomes. Cureus 11(2):e4085. https://doi.org/10.1016/j.brachy.2020.09.002

  50. Harris AA, Wu M, Deirmenjian JM et al (2020) Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life. Brachytherapy S1538-4721(20):30203–8. https://doi.org/10.1016/j.brachy.2018.04.142

  51. Morton G, McGuffin M, Chung HT et al (2020) Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 146:90–96

    Article  CAS  PubMed  Google Scholar 

  52. Harris AA, Korpics M, Sherwani Z, Farroq F, Baldea K, Flanigan R, Harkenrider M, Solanki AA (2020) Patient and physician reported toxicity with two-fraction definitive high dose rate prostate brachytherapy: the impact of implant interval. J Contemp Brachytherapy 12:216. https://doi.org/10.5114/jcb.2020.96861

    Article  PubMed  PubMed Central  Google Scholar 

  53. Palvai S, Harrison M, Shibu Thomas S et al (2015) Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate CAncer (THEPCA) patients and its effects on toxicity and quality of life: protocol of a randomized feasibility trial. JMIR Res Protoc 4(2):e49. https://doi.org/10.2196/resprot.4462

    Article  PubMed  PubMed Central  Google Scholar 

  54. Hoskin PJ, Colombo A, Henry A et al (2013) GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 107(3):325–332

    Article  PubMed  Google Scholar 

  55. Ghadjar P, Oesch SL, Rentsch CA et al (2014) Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer. Radiat Oncol 9:122. https://doi.org/10.1186/1748-717X-9-122

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hsu IC, Hunt D, Straube W et al (2014) Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral dose. Pract Radiat Oncol 4(1):27–34. https://doi.org/10.1016/j.prro.2013.02.011

    Article  PubMed  Google Scholar 

  57. Cendales R, Alwers E, Cifuentes J et al (2015) High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer. J Contemp Brachytherapy 7(1):10–16. https://doi.org/10.5114/jcb.2015.48838

    Article  PubMed  PubMed Central  Google Scholar 

  58. Hsu IC, Bae K, Shinohara K et al (2010) Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 78(3):751–758. https://doi.org/10.1016/j.ijrobp.2009.08.048

    Article  PubMed  PubMed Central  Google Scholar 

  59. Radiation Therapy Oncology Group RTOG 0924. Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase III randomized trial. https://clinicaltrials.gov/ct2/show/NCT01368588 (identification No. NCT02285855)

  60. Morton G, Chung HT, McGuffin M et al (2017) Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 122:87. https://doi.org/10.1016/j.radonc.2016.10.019

    Article  PubMed  Google Scholar 

  61. Jawad MS, Dilworth JT, Gustafson GS et al (2016) Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 94(4):657–666. https://doi.org/10.1016/j.ijrobp.2015.10.011

    Article  PubMed  Google Scholar 

  62. Barkati M, Williams SG, Foroudi F et al (2012) High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial. Int J Radiat Oncol Biol Phys 82(5):1889–1896. https://doi.org/10.1016/j.ijrobp.2010.09.006

    Article  PubMed  Google Scholar 

  63. Gaudet M, Pharand-Charbonneau M, Desrosiers MP, Wright D, Haddad A (2018) Early toxicity and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer. Brachytherapy 17(3):524–529. https://doi.org/10.1016/j.brachy.2018.01.009

    Article  PubMed  Google Scholar 

  64. Åström L, Sandin F, Holmberg L (2018) Good prognosis following a PSA bounce after high dose rate brachytherapy and external radiotherapy in prostate cancer. Radiother Oncol 129(3):561–566. https://doi.org/10.1016/j.radonc.2018.08.011

    Article  PubMed  Google Scholar 

  65. Burchardt W, Skowronek J (2018) Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer. J Contemp Brachytherapy 10(1):1–9. https://doi.org/10.5114/jcb.2018.73786

    Article  PubMed  PubMed Central  Google Scholar 

  66. Tisseverasinghe SA, Crook JM (2018) The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer. Transl Androl Urol 7(3):414–435

    Article  PubMed  PubMed Central  Google Scholar 

  67. Grado GL, Collins JM, Kriegshauser JS et al (1999) Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 53:2–10

    Article  CAS  PubMed  Google Scholar 

  68. Wong WW, Buskirk SJ, Schild SE et al (2006) Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 176:2020–2024

    Article  PubMed  Google Scholar 

  69. Aaronson DS, Yamasaki I, Gottschalk A et al (2009) Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 104:600–604

    Article  PubMed  Google Scholar 

  70. Lee HK, Adams MT, Motta J (2008) Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Brachytherapy 7:17–21

    Article  PubMed  Google Scholar 

  71. Burri RJ, Stone NN, Unger P et al (2010) Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 77:1338–1344

    Article  PubMed  Google Scholar 

  72. Moman MR, van der Poel HG, Battermann JJ et al (2010) Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy 9:119–125

    Article  PubMed  Google Scholar 

  73. Vargas C, Swartz D, Vashi A et al (2014) Salvage brachytherapy for recurrent prostate cancer. Brachytherapy 13:53–58

    Article  PubMed  Google Scholar 

  74. Nguyen PL, Chen MH, D’Amico AV et al (2007) Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer. Cancer 110:1485–1492

    Article  PubMed  Google Scholar 

  75. Peters M, Maenhout M, van der Voort van Zyp JRN et al (2014) Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol 112:77–82

    Article  PubMed  Google Scholar 

  76. Henríquez I, Sancho G, Hervás A et al (2014) Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. Radiat Oncol 9:102

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Kollmeier MA, McBride S, Taggar A et al (2017) Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: a comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. Brachytherapy 16:1091–1098

    Article  PubMed  Google Scholar 

  78. Tharp M, Hardacre M, Bennett R et al (2008) Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 7:231–236

    Article  PubMed  Google Scholar 

  79. Chen CP, Weinberg V, Shinohara K et al (2013) Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 86:324–329

    Article  PubMed  Google Scholar 

  80. Lee B, Shinohara K, Weinberg V et al (2007) Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California–San Francisco experience. Int J Radiat Oncol Biol Phys 67:1106–1112

    Article  PubMed  Google Scholar 

  81. Kukiełka AM, Hetnał M, Dąbrowski T et al (2014) Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure. Strahlenther Onkol 190:165–170

    Article  PubMed  Google Scholar 

  82. Wojcieszek P, Szlag M, Głowacki G et al (2016) Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure. Radiother Oncol 119:405–410

    Article  PubMed  Google Scholar 

  83. Lyczek J, Kawczyńska MM, Garmol D et al (2009) HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer. J Contemp Brachytherapy 1:105–108

    PubMed  PubMed Central  Google Scholar 

  84. Jiang P, van der Horst C, Kimmig B et al (2017) Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: toxicity and 5-year outcome. Brachytherapy 16:186–192

    Article  PubMed  Google Scholar 

  85. Yamada Y, Kollmeier MA, Pei X et al (2014) A phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy 13:111–116

    Article  PubMed  Google Scholar 

  86. Hsu CC, Hsu H, Pickett B et al (2013) Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys 85(2):370–377

    Article  PubMed  Google Scholar 

  87. Boustani A, Pucar D, Saperstein L et al (2018) Molecular imaging of prostate cancer. Br J Radiol 91(1084):20170736

    Article  PubMed  PubMed Central  Google Scholar 

  88. Nguyen P, Devlin P, Beard C et al (2013) High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature. Brachytherapy 12(1):77–83

    Article  PubMed  Google Scholar 

  89. Hepp R, Eggert T, Schabl G et al (2018) Salvage high-dose-rate brachytherapy for prostate cancer persistence after brachytherapy: repeated use of a polyethylene glycol hydrogel spacer. J Contemp Brachytherapy 10:169–173

    Article  PubMed  PubMed Central  Google Scholar 

  90. Peach M, Trifiletti D, Libby B (2016) Systematic review of focal prostate brachytherapy and the future implementation of image-guided prostate HDR brachytherapy using MR-ultrasound fusion. Prostate Cancer 2016:4754031

    Article  PubMed  PubMed Central  Google Scholar 

  91. Murgic J, Morton G, Loblaw A et al (2018) Focal salvage high dose-rate brachytherapy for locally recurrent prostate cancer after primary radiation therapy failure: results from a prospective clinical trial. Int J Radiat Oncol Biol Phys 102(3):561–567

    Article  PubMed  Google Scholar 

  92. Chung HT, Loblaw A, D’Alimonte L et al (2016) Toxicities, quality of life and MRI response to focal salvage HDR prostate brachytherapy for locally recurrent prostate cancer after external-beam radiotherapy. Brachytherapy 15(2016):S179–S180. https://doi.org/10.1016/j.brachy.2016.04.329

    Article  Google Scholar 

  93. Guerif S, Didas O, Vallee M et al (2014) Focal salvage HDR brachytherapy for local prostate cancer recurrence after a primary radiation therapy: early experience of prospective study. Brachytherapy 13(2014):S116–S117. https://doi.org/10.1016/j.brachy.2014.02.419

    Article  Google Scholar 

  94. Zamboglou C, Rischke H-C, Meyer PT et al (2016) Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. J Contemp Brachytherapy 8(3):241–248

    Article  PubMed  PubMed Central  Google Scholar 

  95. Maenhout M, Peters M, van Vulpen M et al (2017) Focal MRI-guided salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer. Technol Cancer Res Treat 16(6):1194–1201

    Article  PubMed  PubMed Central  Google Scholar 

  96. Moman R, van den Berg C, Kruger A et al (2010) Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int J Radiat Oncol Biol Phys 76(3):741–746

    Article  PubMed  Google Scholar 

  97. Kamrava M, Chung M, Kayode O et al (2013) Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs conventional whole-gland treatment. Brachytherapy 12(5):434–441

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

    Authors and Affiliations

    1. Department of Radiation Oncology, Loyola University Chicago, Maywood, IL, USA

      Alexander A. Harris, Kyle Stang, Matthew M. Harkenrider, Derrick Lock, Michael L. Mysz & Abhishek A. Solanki

    2. Loyola University Medical Center, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA

      Alexander A. Harris, Kyle Stang, Matthew M. Harkenrider, Derrick Lock, Michael L. Mysz & Abhishek A. Solanki

    3. Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA

      Mitchell Kamrava

    4. Department of Radiation Oncology, Sunnybrook Health Sciences Center, Toronto, ON, Canada

      Gerard Morton

    5. Department of Radiation Oncology, University of Virginia School of Medicine, Charlottesville, VA, USA

      Timothy Showalter

    6. Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA

      Anthony C. Wong

    Authors
    1. Alexander A. Harris
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Kyle Stang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Matthew M. Harkenrider
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Mitchell Kamrava
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Derrick Lock
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Gerard Morton
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Michael L. Mysz
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Timothy Showalter
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Anthony C. Wong
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Abhishek A. Solanki
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Abhishek A. Solanki .

    Editor information

    Editors and Affiliations

    1. Department of Radiation Oncology, Loyola University Chicago, Maywood, IL, USA

      Abhishek A. Solanki

    2. Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA

      Ronald C. Chen

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2021 Springer Nature Switzerland AG

    About this chapter

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this chapter

    Harris, A.A. et al. (2021). High Dose Rate Prostate Brachytherapy. In: Solanki, A.A., Chen, R.C. (eds) Radiation Therapy for Genitourinary Malignancies . Practical Guides in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-65137-4_6

    Download citation

    • DOI: https://doi.org/10.1007/978-3-030-65137-4_6

    • Published:

    • Publisher Name: Springer, Cham

    • Print ISBN: 978-3-030-65136-7

    • Online ISBN: 978-3-030-65137-4

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation